

## MEDICAL PRACTICE

---

*Contemporary Themes*

---

**Drugs taken by mothers in the puerperium: inpatient survey in Northern Ireland**

CLARE M PASSMORE, JAMES C McELNAY, PATRICK F D'ARCY

**Abstract**

In an inpatient survey the medication records of 2004 mothers both breast and bottle feeding were examined and the drugs taken in the early postnatal period recorded. No notable differences existed between the types of drugs prescribed for breast feeding and bottle feeding mothers. Iron, vitamins, and mild analgesics were taken routinely by the population, and antibiotics, laxatives, and hypnotics were frequently prescribed. A wide range of other drugs and preparations were taken or used. Although data were available for some of the drugs, there were many whose concentrations in breast milk and potential risk to the suckling infant were unknown.

Data are urgently required on hypnotics, narcotic analgesics, antiemetics, antihistaminics, and some antimicrobial agents with respect to their concentrations in breast milk and their safety for the suckling infant.

**Introduction**

During the past decade there has been a considerable increase in the number of mothers breast feeding their newborn; for example, a study in Harrow found an increase from 38% in 1972 to 69% in 1976.<sup>1</sup> A later report from Sheffield showed that the numbers had plateaued at about 69%.<sup>2</sup> The authors of that study concluded that the educational programme alerting mothers to the benefits of

breast feeding had been largely successful, although they cautioned that further progress could be made.

Unfortunately, some suckling infants react to specific substances excreted in human milk; these include food allergens, environmental pollutants, and drugs. Adverse effects attributed to drugs in milk vary in severity and include diarrhoea, irritability, sedation, convulsions, metabolic acidosis, anaemia, and allergic sensitisation to antibiotics.<sup>3</sup>

The problem of drug excretion in breast milk and the associated adverse effects in the suckling infant have received increasing attention over the past few years and several review articles have summarised the currently available information.<sup>3-5</sup> The reviewers, however, emphasise that many of the early reports on drug excretion in milk were inadequate owing to poor assay techniques and that few pharmacokinetic based studies have been carried out. Clearly, therefore, many of the present recommendations on whether to breast feed or not during medication are based on isolated and often anecdotal case reports. Two reasons for the paucity of relevant studies are the complexities of obtaining serum and milk samples from new mothers and an apparent lack of interest on the part of clinicians.<sup>6</sup>

A further major problem is the complete lack of statistical information on the range of drugs taken by mothers in the immediate postpartum period. Information of this type is required so that a systematic approach may be made to further work. Our aim was therefore to obtain and document information and to highlight those drugs for which detailed data on breast milk excretion are urgently required.

**Method**

The survey was carried out in three major maternity units in Belfast: the Jubilee Maternity Hospital, the Royal Maternity Hospital, and the maternity unit of The Ulster Hospital, Dundonald. Approval for the survey was obtained from the ethical committee of the faculty of medicine, The Queen's University of Belfast, and data were collected with the full coopera-

---

**The Queen's University of Belfast, Northern Ireland**

CLARE M PASSMORE, BSC, MPSNI, postgraduate student, department of pharmacy  
JAMES C McELNAY, BSC, PHD, lecturer in biopharmacy, department of pharmacy  
PATRICK F D'ARCY, PHD, DSC, professor of pharmacy; dean, faculty of science

Correspondence to: Professor Patrick F D'Arcy, Department of Pharmacy, The Queen's University of Belfast, Medical Biology Centre, Belfast BT9 7BL, Northern Ireland.

---





conjugation with fats, lipases, and steroids excreted in milk.<sup>19</sup> Thus the excretion of progesterones in milk may increase the risk of neonatal jaundice, and monitoring for hyperbilirubinaemia would be a wise precaution. It may even be suggested that children should be monitored to puberty and beyond for side effects similar to those reported for intrauterine exposure to stilboestrol.<sup>20</sup>

We were interested to note that bottle feeding mothers were much more likely to receive iron and vitamin preparations. No reason for this was found.

In conclusion, this survey has documented the range of drugs normally prescribed in the immediate postpartum period. In doing so, it has highlighted those drugs which require further study with respect to their concentrations in breast milk and their safety or hazard to the suckling infant. These drugs are hypnotics, narcotic analgesics, antiemetics, antihistaminics, and some antimicrobial agents.

It is well recognised, however, that this short list of drugs may represent only the "tip of an iceberg," many mothers perhaps receiving other prescribed or over the counter drugs after discharge from the maternity units. We think that retrieval of this latter information could be best achieved with the help of community midwives, health visitors, and general practice pharmacists. It is from those groups that we are currently seeking help for a complementary and ongoing outpatient study.

## References

- 1 Coles EC, Valman HB. Breast feeding in Harrow. *Lancet* 1976;ii:583.
- 2 Taitz LS. Breast feeding trends in Sheffield 1976-82. *Br Med J* 1983;287:648.
- 3 Chaplin S, Sanders GL, Smith JM. Drug excretion in human milk. *Advances in Drug Reactions and Acute Poisons Review* 1982;1:255-87.
- 4 D'Arcy PF, McElroy JC. Drugs in milk. In: D'Arcy PF, Griffin JP, eds. *Iatrogenic diseases*. 2nd ed. Update 1983. Oxford: Oxford University Press, 1983:181-9.
- 5 Wilson JT, Brown RD, Cherek DR, et al. Drug excretion in human breast milk. Principles, pharmacokinetics and projected consequences. *Clin Pharmacokinet* 1980;5:1-66.
- 6 Knowles JA. Excretion of drugs in milk—a review. *J Pediatr* 1965;66:1068-82.
- 7 Postellon DC, Aronok K. Iodine in mothers' milk. *JAMA* 1982;247:463.
- 8 Traeger A, Peiker G. Excretion of nalidixic acid via mothers' milk. *Arch Toxicol* 1980;45:388-90.
- 9 Food and Drugs Administration. Metronidazole (Flagyl) box warning. *FDA Drug Bulletin* 1976;6:22-3.
- 10 Heisterberg L, Braneberg PE. Blood and milk concentrations of metronidazole in mothers and infants. *J Perinat Med* 1983;11:114-20.
- 11 Joint Formulary Committee. Prescribing during breast-feeding. *British National Formulary*. No 7. London: British Medical Association, The Pharmaceutical Society of Great Britain, 1984:19-22.
- 12 Bailey DN, Weibert RT, Naylor AJ, Shaw RF. A study of salicylate and caffeine excretion in the breast milk of two nursing mothers. *J Anal Toxicol* 1982;6:64-8.
- 13 Berlin CM, Yaffe SJ, Ragni M. Disposition of acetaminophen in milk, saliva and plasma of lactating women. *Pediatr Pharmacol (New York)* 1980;1:135-41.
- 14 Bitzen PO, Gustafsson B, Jostell KG, Melander A, Wahlin-Boll E. Excretion of paracetamol in human breast milk. *Eur J Clin Pharmacol* 1981;20:123-5.
- 15 Findlay JW, De Angelis R, Kearney MF, Welsh RM, Findlay JM. Analgesic drugs in breast milk and plasma. *Clin Pharmacol Ther* 1981;29:625-33.
- 16 Knowles JA. Breast milk: a source more than nutrition for the neonate. *Clinical Toxicology* 1974;7:69-82.
- 17 Kok THHG, Taitz LS, Bennett MJ, Holt DW. Drowsiness due to clemastine transmitted in breast milk. *Lancet* 1982;ii:913-4.
- 18 Saxena BN, Shrimanker K, Grudzinskas JG. Levels of contraceptive steroids in breast milk and plasma of lactating women. *Contraception* 1977;16:605-13.
- 19 Thaler MM. Jaundice in the newborn. *JAMA* 1977;237:58-62.
- 20 Herbst AL, Scully RE. Adenocarcinoma of the vagina in adolescents. *Cancer* 1970;25:745-61.

(Accepted 12 September 1984)

# A layman's guide to grommets

DAVID M EAST

## Introduction

The use of prostheses to establish and maintain ventilation of the middle ear cleft in patients suffering from secretory otitis media (also called seromucinous otitis and glue ear) is a remarkable feature of current otological practice compared with that of 25 years ago. The number of patients presenting with this condition may have increased sufficiently to stimulate the growth of an entire industry catering for the design and manufacture of ventilation tubes, but the problem was recognised, albeit on a smaller scale, by an earlier generation of ear, nose, and throat surgeons, whose attempts to treat persistent secretory otitis media were frustrated by the lack of suitable techniques for maintaining patency of myringotomy incisions. The efforts made by successive generations of otologists both to close some perforations and simultaneously to keep others from closing spontaneously must have caused a certain amount of amusement among non-otologists over the years. Indeed, the ingenuity displayed in attempting the second goal has been quite remarkable.

In 1801 Sir Astley Cooper obtained the Copley Medal of the Royal Society for his work on the value of myringotomy for the relief of deafness. Toynbee, the great 19th century otologist, described a method of punching out a circular hole in the eardrum, which he attributed to Fabrizzi. He also described his own method of raising a triangular flap in the tympanic membrane but acknowledged that the results would only be permanent in the presence of a functioning eustachian tube.<sup>1</sup> Ballin described the attempts of others to maintain

an artificial perforation.<sup>2</sup> Devices used included catgut, fishbone plugs, lead wires, silver cannulas, rubber plugs, and small gold tubes. Because these and other methods were unsuccessful the subject fell in to abeyance until interest was rekindled in 1954 by Armstrong,<sup>3</sup> who used a vinyl plastic tube, 1.5 mm in diameter, left in situ for four weeks.

## What ventilation tubes are available?

It is convenient to divide ventilation tubes into two types; those for medium term use, which are grommet shaped, and those for long term use—that is, for use in patients with permanent obstruction of the eustachian tube—which are tube shaped with a flange medial to the eardrum. The key to longevity is the size of the flange. All other things being equal, a tube with a large inner flange will remain in situ for a longer time than one with a small flange. Thus the length of time the tube ought to stay in place can, to an extent, be determined preoperatively.

The grommet most often used is the Shepard grommet (fig 1). It has three features of specific importance. The outer flange is thick to minimise deformation when it is grasped by crocodile forceps during insertion; the inner flange is thin to locate easily in the myringotomy incision; and a wire is attached to facilitate manipulation of the grommet in the confines of the external auditory meatus. Shepard grommets are also available without the wire and in a choice of four colours (red, blue, green, and white). The colour is of no significance. The Shah grommet (fig 1) has a larger flange than the Shepard grommet both to promote longevity and to aid insertion.

For the "average" case of secretory otitis media grommets similar to those described are quite satisfactory. The problem arises when, after meticulous attention to the nasopharynx and upper respiratory mucosa in general, the ear continues to deteriorate and grommets do not provide a suitable answer. At some arbitrary stage a decision is

Department of Otorhinolaryngology, Scarborough Hospital, Scarborough, North Yorkshire

DAVID M EAST, MA, FRCS, consultant ENT surgeon